MARKETRESEARCH
Uploaded on Apr 15, 2024
Category
Health & Medicine
According to the latest research report by IMARC Group, The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. More Info:- https://www.imarcgroup.com/human-insulin-market
Category
Health & Medicine
Human Insulin Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
Global Human Insulin
Market Research and
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved
About IMARC Group
In ternat ional Market Analys is Research and Consul t ing Group is a leading adv iser on management
s t rategy and market research wor ldwide. We par tner wi th c l ients in a l l regions and indust ry
vert ica ls to ident i fy thei r h ighest -value oppor tuni t ies, address thei r most cr i t ica l chal lenges, and
t ransform thei r bus inesses.
IMARC’s in format ion products inc lude major market , sc ient i f ic , economic and technological
developments for bus iness leaders in pharmaceut ica l , indust r ia l , and h igh technology
organizat ions. Market forecasts and indust ry analys is for b iotechnology, advanced mater ia ls ,
chemicals , food and beverage, t ravel and tour ism, nanotechnology and novel process ing methods
are at the top of the company’s exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight in to the dynamics o f companies and
markets wi th c lose cooperat ion at a l l levels of the c l ient organizat ion. This ensures that our c l ients
achieve unmatchable compet i t ive advantage, bui ld more pro f ic ient organizat ions, and secure
las t ing resul ts .
Accord ing to t he la t es t repor t by I MARC Group, t i t l ed " Human I nsu l i n Market :
G loba l I ndust ry T rends , Share , S ize , Grow th , Opportun i ty and Forecast 2024-
2032, " t he g loba l human insu l in m arke t s i ze reached US$ 48 .2 B i l l i on i n 2023.
Human i nsu l in (H I ) , a l so known as regu la r insu l in , r e f e r s t o sho r t -ac t ing insu l in
Report syn thes ized in l abora t o r ies . I t m im ics the func t ion o f i nsu l i n na tu ra l l y p roduced
by t he human body and i s genera l l y in j ec ted subcu taneous ly mu l t ip le t imes a day .
Highlight and I t i s b io -eng ineered by g rowing insu l in p ro t e ins w i t h in E -co l i bac te r ia (Escher i ch ia co l i ) ce l l s .
I t i s w ide ly used to regu la t e b lood sugar leve ls in pa t i en ts w i t h t ype I and I I
Description d iabet es and p romote g lucose up take f rom the b lood in to i n t e rna l o rgans and
t i s sues , such as l i ve r and f a t ce l l s . I t a l so i nh ib i t s hepa t i c g lucose p roduc t ion and
enhances the p ro te in syn t hes i s o f t he body .
Request fo r a PDF sample o f th is repor t :
ht tps : / / www. imarcgroup .com/human- insu l in -marke t / r eques tsam ple
Report Description
G l o b a l H u m a n I n s u l i n M a r k e t T r e n d s :
T h e s u r g i n g i n c i d e n c e s o f d i a b e t e s d u e t o t h e a g i n g p o p u l a t i o n , s e d e n t a r y l i f e s t y l e s , a n d u n h e a l t h y d i e t a r y h a b i t s r e p r e s e n t t h e
p r i m a r y f a c t o r d r i v i n g t h e m a r k e t g r o w t h . A d d i t i o n a l l y , t h e r e h a s b e e n g r o w i n g c o n s u m e r a w a r e n e s s r e g a r d i n g t h e c o m p l i c a t i o n s o f
p r o l o n g e d d i a b e t e s , s u c h a s c a t a r a c t s , h e a r t a t t a c k s , a n d k i d n e y f a i l u r e . I n l i n e w i t h t h i s , t h e e s c a l a t i n g d e m a n d f o r b i o s i m i l a r d r u g s
o n a c c o u n t o f t h e i r h i g h e f f i c i e n c y a n d c o s t - e f f e c t i v e n e s s h a s c a t a l y z e d m a r k e t g r o w t h . F u r t h e r m o r e , s e v e r a l k e y p l a y e r s a r e
e x t e n s i v e l y i n v e s t i n g i n r e s e a r c h a n d d e v e l o p m e n t ( R & D ) a c t i v i t i e s t o d e v e l o p o r a l i n s u l i n v a r i a n t s t h a t p r o v i d e a s a f e , e f f e c t i v e , a n d
c o n v e n i e n t m e t h o d o f d e l i v e r i n g i n s u l i n t h e r a p y . A p a r t f r o m t h i s , t h e i n t r o d u c t i o n o f p e n d e v i c e s a n d s a f e t y p e n n e e d l e s t h a t c a u s e
m i n i m a l d i s c o m f o r t a n d r e d u c e t h e r i s k s o f i n j u r i e s , i n f e c t i o n s , a n d b l o o d b o r n e p a t h o g e n t r a n s m i s s i o n h a s a c c e l e r a t e d t h e p r o d u c t
a d o p t i o n r a t e . M o r e o v e r , t h e i m p l e m e n t a t i o n o f s t r i n g e n t g o v e r n m e n t p o l i c i e s a g a i n s t n e e d l e s t i c k i n j u r i e s a n d t h e s h i f t i n g c o n s u m e r
p r e f e r e n c e s t o w a r d m i n i m a l l y i n v a s i v e ( M I ) d e v i c e s h a v e e n c o u r a g e d t h e u s a g e o f p e n d e v i c e s a n d s a f e t y p e n n e e d l e s f o r H I
a d m i n i s t r a t i o n . O t h e r f a c t o r s , i n c l u d i n g t h e e x p a n d i n g o b e s e p o p u l a t i o n , i m p r o v i n g h e a l t h c a r e i n f r a s t r u c t u r e , i n c r e a s i n g c o n s u m e r
h e a l t h c o n s c i o u s n e s s , r e c e n t a d v a n c e m e n t s i n t h e b i o t e c h n o l o g y f i e l d , a n d p r o d u c t i n n o v a t i o n s , a r e a l s o p r o v i d i n g a p o s i t i v e t h r u s t t o
t h e m a r k e t g r o w t h .
L o o k i n g f o r w a r d , t h e m a r k e t v a l u e i s e x p e c t e d t o r e a c h U S $ 8 4 . 2 B i l l i o n b y 2 0 3 2 , e x h i b i t i n g a C A G R o f 6 . 2 % d u r i n g t h e f o r e c a s t
p e r i o d ( 2 0 2 4 - 2 0 3 2 ) .
V i e w R e p o r t T O C , F i g u r e s a n d T a b l e s : h t t p s : / / w w w . i m a r c g r o u p . c o m / h u m a n - i n s u l i n - m a r k e t
Breakup by Product Type:
• Drugs
o Human Insul in Analogs and Biosimilars
• Rapid Acting
• Long Act ing
• Premixed
o Human Insul in Biologics
Report
• Short Act ing
Segmentation • Intermediate Act ing
• Premixed
• Del ivery Devices
o Pens
• Reusable Pens
• Disposable Pens
o Pen Needles
• Standard Pen Needles
• Safety Pen Needles
o Syringes
o Others
Breakup by Distribution Channel:
• Retai l Pharmacies
Report
• Hospital Pharmacies
Segmentation • Online Retai l Stores
• Others
Breakup by Disease Type:
• Type I Diabetes
• Type I I Diabetes
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
Report • Middle East and Afr ica
Segmentation
• B. Braun Melsungen AG
• Becton, Dickinson and Company (BD)
• Biocon
Competitive • El i Li l ly and Company
Landscape • Gulf Pharmaceutical Industr ies ( Julphar)
• Novo Nordisk A/S
with Key • Pfi zer Inc.
Players • Groupe Sanofi
• SEDICO Co.
• Wockhardt Limited
• Ypsomed AG
What was the size of the global human insulin
market in 2023?
What is the expected growth rate of the global
human insulin market during 2024-2032?
What are the key factors driving the global human
insulin market?
Key
What has been the impact of COVID-19 on the
Questions global human insulin market?
Answered in What is the breakup of the global human insulin market based on the product type?
the Report What is the breakup of the global human insulin
market based on the distribution channel?
What is the breakup of the global human insulin
market based on the disease type?
What are the key regions in the global human
insulin market?
Who are the key players/companies in the global
human insulin market?
1 P r e f a c e
2 S c o p e a n d M e t h o d o l o g y
2 . 1 O b j e c t i v e s o f t h e S t u d y
2 . 2 S t a k e h o l d e r s
2 . 3 D a t a S o u r c e s
2 . 3 . 1 P r i m a r y S o u r c e s
2 . 3 . 2 S e c o n d a r y S o u r c e s
2 . 4 M a r k e t E s t i m a t i o n
2 . 4 . 1 B o t t o m - U p A p p r o a c h
Table of 2 . 4 . 2 T o p - D o w n A p p r o a c h 2 . 5 F o r e c a s t i n g M e t h o d o l o g y
3 E x e c u t i v e S u m m a r y
4 I n t r o d u c t i o n
4 . 1 O v e r v i e w
Contents 4 . 2 K e y I n d u s t r y T r e n d s5 G l o b a l H u m a n I n s u l i n M a r k e t
5 . 1 M a r k e t O v e r v i e w
5 . 2 M a r k e t P e r f o r m a n c e
5 . 3 I m p a c t o f C O V I D - 1 9
5 . 4 M a r k e t F o r e c a s t
6 M a r k e t B r e a k u p b y P r o d u c t T y p e
6 . 1 D r u g s
6 . 1 . 1 M a r k e t T r e n d s
6 . 1 . 2 M a r k e t B r e a k u p b y T y p e
6 . 1 . 2 . 1 H u m a n I n s u l i n A n a l o g s a n d B i o s i m i l a r s
6 . 1 . 2 . 1 . 1 R a p i d A c t i n g
6 . 1 . 2 . 1 . 1 . 1 M a r k e t T r e n d s
6 . 1 . 2 . 1 . 1 . 2 M a r k e t F o r e c a s t
6 . 1 . 2 . 1 . 2 L o n g A c t i n g
6 . 1 . 2 . 1 . 2 . 1 M a r k e t T r e n d s
6 . 1 . 2 . 1 . 2 . 2 M a r k e t F o r e c a s t
6 . 1 . 2 . 1 . 3 P r e m i x e d
6 . 1 . 2 . 1 . 3 . 1 M a r k e t T r e n d s
6 . 1 . 2 . 1 . 3 . 2 M a r k e t F o r e c a s t
6 . 1 . 2 . 2 H u m a n I n s u l i n B i o l o g i c s
6 . 1 . 2 . 2 . 1 S h o r t A c t i n g
6 . 1 . 2 . 2 . 1 . 1 M a r k e t T r e n d s
6 . 1 . 2 . 2 . 1 . 2 M a r k e t F o r e c a s t
6 . 1 . 2 . 2 . 2 I n t e r m e d i a t e A c t i n g
6 . 1 . 2 . 2 . 2 . 1 M a r k e t T r e n d s
6 . 1 . 2 . 2 . 2 . 2 M a r k e t F o r e c a s t
6 . 1 . 2 . 2 . 3 P r e m i x e d
6 . 1 . 2 . 2 . 3 . 1 M a r k e t T r e n d s
Table of 6 . 1 . 2 . 2 . 3 . 2 M a r k e t F o r e c a s t
6 . 1 . 3 M a r k e t F o r e c a s t
6 . 2 D e l i v e r y D e v i c e s
Contents 6 . 2 . 1 M a r k e t T r e n d s 6 . 2 . 2 M a r k e t B r e a k u p b y T y p e
6 . 2 . 2 . 1 P e n s
6 . 2 . 2 . 1 . 1 R e u s a b l e P e n s
6 . 2 . 2 . 1 . 2 D i s p o s a b l e P e n s
6 . 2 . 2 . 2 P e n N e e d l e s
6 . 2 . 2 . 2 . 1 S t a n d a r d P e n N e e d l e s
6 . 2 . 2 . 2 . 2 S a f e t y P e n N e e d l e s
6 . 2 . 2 . 3 S y r i n g e s
6 . 2 . 2 . 4 O t h e r s
6 . 2 . 3 M a r k e t F o r e c a s t
7 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l
7 . 1 R e t a i l P h a r m a c i e s
7 . 1 . 1 M a r k e t T r e n d s
7 . 1 . 2 M a r k e t F o r e c a s t
F o r m o r e i n f o r m a t i o n , v i s i t :
h t t p s : / / w w w. im a rcg ro u p . co m / h u m a n - i n s u l i n - m a r ke t / t o c
Disclaimer
© 2023 IMARC Al l R ights Reserved
Th is Pub l i ca t ion and a l l i t ’ s con ten ts un less o therw ise men t i oned a re copy r i gh ted in the name o f
I n t e rna t i ona l Marke t Ana lys i s Research and Consu l t ing ( IMARC) . No pa r t o f t h i s pub l i ca t ion may be
rep roduced , repackaged , red i s t r i bu ted o r res o ld i n who le o r i n any pa r t . The pub l i ca t ion may a l so
no t be used i n any f o rm o r by and means g raph i c e lec t ron ic o r mechan ic a l , i nc lud ing pho tocopy ing ,
reco rd ing , t ap ing o r by i n fo rmat i on s to rage o r re t r ieva l , o r by any o the r f o rm, w i t hou t the exp ress
c ons en t o f I n t e rna t iona l Marke t Ana lys i s Research and Consu l t i ng ( IMARC) .
Disc la imer : Al l con ten ts and da ta o f t h i s pub l i c a t i on , i nc lud ing fo recas t s , da ta ana lys i s and op in ion
have been based on in f o rmat ion and sources be l ieved to be accu ra te and re l iab le a t t he t ime o f
pub l i sh ing . In t e rna t i ona l Ma rke t Ana l ys is Research and Consu l t ing makes no rep resen ta t ion o f
war ran t y o f any k ind as to t he acc u racy o r comp le teness o f any I n fo rmat i on p rov ided . IMARC
accep ts no l i ab i l i t y wha tsoever f o r any los s o r damage resu l t i ng f rom op in ion , e r ro rs o r
i naccu rac ies i f any f ound th is pub l i ca t ion .
IMARC, IMARC Group and G loba l Therapy I ns igh t Ser i es a re reg is t e red t rademarks o f I n te rna t iona l
Marke t Ana lys i s Research and Consu l t ing . A l l o the r t rademarks used i n th i s pub l i ca t i on a re
reg i s te red t rademarks o f t he i r r espec t i ve compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: [email protected]
Comments